What is ControlRad?
Headquartered in Norcross, Georgia, ControlRad specializes in the development of advanced imaging solutions designed to minimize radiation exposure. The company's core technology addresses the inherent risks associated with both fixed and mobile C-arm procedures, which are staples in surgical and diagnostic imaging. By integrating sophisticated software and hardware, ControlRad enables healthcare providers to perform complex interventions with a significantly reduced radiation footprint. This focus on safety and operational efficiency places the company at the intersection of medical device innovation and clinical risk management, serving a vital need in hospitals and surgical centers globally. As the demand for safer, high-precision imaging grows, ControlRad's market position is bolstered by its commitment to reducing the lifetime risk of radiation exposure for both patients and medical professionals.
How much funding has ControlRad raised?
ControlRad has raised a total of $22M across 3 funding rounds:
Series A
$3M
Series B
$15M
Debt
$4M
Series A (2017): $3M, investors not publicly disclosed
Series B (2019): $15M led by Questa Capital
Debt (2020): $4M supported by SVB Financial Group
Key Investors in ControlRad
Questa Capital
Questa Capital is a venture firm focused on innovative healthcare companies that aim to enhance patient experiences, reduce costs, and improve overall population health.
SVB Financial Group
SVB Financial Group provides commercial and private banking, asset management, and investment services tailored to the needs of the innovation economy.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for ControlRad?
With the recent influx of capital, ControlRad is well-positioned to scale its commercial operations and accelerate the adoption of its radiation-reduction technology. The company's growth trajectory, marked by a series of strategic financing rounds, suggests a transition toward broader market penetration and potential integration into standard-of-care protocols for C-arm imaging. Future initiatives will likely focus on expanding the reach of its proprietary solutions, enhancing product capabilities, and strengthening its footprint in the competitive medical imaging landscape. By leveraging its recent investment, the firm aims to solidify its status as a leader in radiation safety, ensuring that its innovative tools become an essential component of the modern surgical suite.
See full ControlRad company page
